Ranbaxy set to launch India's first malaria drug
Drug major Ranbaxy has successfully completed the phase II clinical trials for the first malaria drug being developed in the country.
By ET Bureau |
NEW DELHI: India may have its own anti-malaria drug soon. Drug major Ranbaxy has successfully completed the phase II clinical trials for the first malaria drug being developed in the country. The company is expected to start marketing the drug three to five years from now.
���The proof-of-phasing for phase II of the trials have been successfully undertaken and the drug will now undergo phase III of trials before being introduced in the market,��� Ranbaxy���s senior VP for new drug discovery research Pradip Bhatnagar said on the sidelines of a seminar.
Ranbaxy has been working on the anti-malaria segment since May 2003. Earlier, it was a collaborative research project with the Geneva-based Medicines for Malaria Venture (MMV) to develop the synthetic peroxide anti-malarial drug but MMV walked out of the joint project in November 2007.
The company has not yet decided on any trade name for the drug research. The company plans to export the anti-malaria drug to Asian, African and South American countries at an affordable cost. Despite having a large market for malaria in developing countries, the market segment has very limited resources, an industry expert said. Together with the challenges of drug resistance, poor health systems, lack of affordable, safe and convenient treatment options, malaria treatment represents one of the largest unmet medical needs of developing countries.a
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
